R3 Stem Cell Now Offering Regenerative Therapy for Post Stroke Patients

*R3 Stem Cell is now offering effective regenerative medicine therapies for post stroke patients. The procedures are performed by Double Board Certified physicians at the R3 Stem Cell Center of Excellence in Las Vegas.*

LAS VEGAS (PRWEB) July 18, 2018 -- R3 Stem Cell is now offering effective regenerative medicine therapies for post stroke patients. The procedures are performed by Double Board Certified physicians at the R3 Stem Cell Center of Excellence in Las Vegas.

Each year close to 800,000 individuals in the US suffer a stroke, which amounts to one every 40 seconds. Traditional thinking has been that patients have approximately eighteen months to achieve maximal recovery after a stroke, and then are left with residual deficits.

Stem cell therapy for stroke is showing to be effective for helping patients recover well after the eighteen month time frame. Excellent studies such as the recent one out of Stanford showed that patients achieved excellent improvements in motor function even years afterwards.

In addition, the stem cell therapies for stroke have been shown to be safe for patients, with no significant complications. R3 Stem Cell offers a patient concierge service, which entails a complimentary phone or in person consultation along with a medical record review.

The biologic material used is FDA regulated, with no embryonic stem cells being used. R3 Stem Cell has an industry leading safety record.

Overall, R3 Stem Cell has successfully treated over 10,000 patients with regenerative procedures at over 30 Centers nationwide. Treatments are offered for arthritis, autoimmune conditions, organ failure, neurodegenerative conditions, neuropathy and more.

Call (844) GET-STEM to get set up for the complimentary consultation with R3’s Board Certified providers to see about being a candidate.
Contact Information
David Greene, MD, MBA
R3 Stem Cell
http://r3stemcell.com
+1 (602) 677-8981

Online Web 2.0 Version
You can read the online version of this press release here.